Search

Your search keyword '"Tetrazoles pharmacology"' showing total 5,766 results

Search Constraints

Start Over You searched for: Descriptor "Tetrazoles pharmacology" Remove constraint Descriptor: "Tetrazoles pharmacology"
5,766 results on '"Tetrazoles pharmacology"'

Search Results

251. Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial.

252. The effect of candesartan on chronic stress induced imbalance of glucose homeostasis.

253. Mechanisms involved in the antinociceptive and anti-inflammatory effects of a new triazole derivative: 5-[1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl]-1H-tetrazole (LQFM-096).

254. Effectiveness of Olmesartan on Blood Pressure Control in Hypertensive Patients in India: A Real World, Retrospective, Observational Study from Electronic Medical Records.

255. Protective effects of irbesartan and benazepril against vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats.

256. Tetrazoles as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies.

257. Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension.

258. Impact of Sacubitril-Valsartan on Markers of Glomerular Function.

259. The BK activator NS11021 partially protects rat kidneys from cold storage and transplantation-induced mitochondrial and renal injury.

260. Positive allosteric modulation of GABA A receptors by a novel antiepileptic drug cenobamate.

261. Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.

262. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.

263. ACE (Angiotensin-Converting Enzyme) Inhibition Reverses Vasoconstriction and Impaired Dilation of Pial Collaterals in Chronic Hypertension.

264. An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension.

265. Candesartan ameliorates vascular smooth muscle cell proliferation via regulating miR-301b/STAT3 axis.

266. Opening large-conductance potassium channels selectively induced cell death of triple-negative breast cancer.

267. Molecular mechanism of BK channel activation by the smooth muscle relaxant NS11021.

268. Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers.

269. Antiamoebic activity of synthetic tetrazoles against Acanthamoeba castellanii belonging to T4 genotype and effects of conjugation with silver nanoparticles.

270. LCZ696 (sacubitril/valsartan) protects against cyclophosphamide-induced testicular toxicity in rats: Role of neprilysin inhibition and lncRNA TUG1 in ameliorating apoptosis.

271. Olmesartan attenuates type 2 diabetes-associated liver injury: Cross-talk of AGE/RAGE/JNK, STAT3/SCOS3 and RAS signaling pathways.

272. ARNIs: balancing "the good and the bad" of neuroendocrine response to HF.

273. House dust mite allergens induce interleukin 33 (IL-33) synthesis and release from keratinocytes via ATP-mediated extracellular signaling.

274. Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?

275. A General Strategy for Macrotheranostic Prodrug Activation: Synergy between the Acidic Tumor Microenvironment and Bioorthogonal Chemistry.

276. Tedizolid as Step-Down Therapy following Daptomycin versus Continuation of Daptomycin against Enterococci and Methicillin- and Vancomycin-Resistant Staphylococcus aureus in a Rat Endocarditis Model.

277. Characterization of a novel compound that promotes myogenesis via Akt and transcriptional co-activator with PDZ-binding motif (TAZ) in mouse C2C12 cells.

278. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.

279. Involvement of Angiotensin II Type 1 Receptor and Calcium Channel in Vascular Remodeling and Endothelial Dysfunction in Rats with Pressure Overload.

280. Protective effects of olmesartan and l-carnitine on doxorubicin-induced cardiotoxicity in rats.

281. Leukotriene B 4 Receptor Type 2 Accelerates the Healing of Intestinal Lesions by Promoting Epithelial Cell Proliferation.

282. Assessment of Tedizolid In Vitro Activity and Resistance Mechanisms against a Collection of Enterococcus spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018.

283. Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor.

284. Candesartan Neuroprotection in Rat Primary Neurons Negatively Correlates with Aging and Senescence: a Transcriptomic Analysis.

285. Single-pill combination of cilnidipine, an L-/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE-Combi survey.

286. In vitro and in vivo effects of 5-aminotetrazole (5-AT), an energetic compound.

287. Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor.

288. High-dose nitrate therapy recovers the expression of subtypes α 1 and β-adrenoceptors and Ang II receptors of the renal cortex in rats with myocardial infarction-induced heart failures.

289. In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan.

290. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.

291. Novel 5-(1-aryl-1H-pyrazol-3-yl)-1H-tetrazoles as glycogen phosphorylase inhibitors: An in vivo antihyperglycemic activity study.

292. Prostaglandin E 2, a postulated mediator of neurovascular coupling, at low concentrations dilates whereas at higher concentrations constricts human cerebral parenchymal arterioles.

293. Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study).

294. Development of (4-methoxyphenyl)-1H-tetrazol-5-amine regioisomers as a new class of selective antitubercular agents.

295. LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice.

297. Discovery of metyltetraprole: Identification of tetrazolinone pharmacophore to overcome QoI resistance.

298. Bronchodilation induced by PGE 2 is impaired in Group III pulmonary hypertension.

300. Auxiliary subunits control biophysical properties and response to compound NS5806 of the Kv4 potassium channel complex.

Catalog

Books, media, physical & digital resources